CPHI

China Pharma Holdings Inc. Common Stock (CPHI)

Stock · AMEX · Health Care

$0.6916as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 7, 2026

CPHI listed among top gainers and losers before market close. A recent ChartMill snapshot of the top gainers and losers an hour before the market closed included CPHI. The mention shows the stock had notable price movement in the session. The stock is currently near its 20‑touch support level of $0.63 and its RSI sits at 43.2, indicating modest momentum.

Active signals

Support level
$0.625625
Industry
Biotechnology: Pharmaceutical Preparations

What CPHI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike35-11.1%29%
Bollinger Band Breakdown24-3.1%46%
Bollinger Band Breakout17-16.7%18%
200-Day Moving Average TouchActive now6-14.5%0%
Any 20-session window (baseline)-8.4%28%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About CPHI

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness,…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
215

Fundamentals

1-day range
$0.6743$0.7373
Market cap
$52.06M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
$-0.43
Dividend yield
—
Beta
0.98
Avg. volume
3.87M
52-week range
$0.3818$19.19

How China Pharma Holdings Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$4.14MCost of Revenue$4.28M (103%)SG&A$2.45M (59%)R&D$280.9K (7%)CPHI

Source: 10-K filed Apr 1, 2026 · via SEC EDGAR / Finnhub

Gross Profit-$131.9K(-3%)
Operating Income-$3.24M(-78%)

China Pharma Holdings Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • CPHI
    China Pharma Holdings Inc. Common Stock
    $0.71
    ▼ 2.74%
    Market cap $52.06MP/E —
    $0.3818$19.19
  • RNXT
    RenovoRx Inc. Common Stock
    $1.14
    ▼ 4.20%
    Market cap $51.86MP/E —
    $0.7006$2.59
  • SCYX
    SCYNEXIS Inc. Common Stock
    $3.67
    ▼ 6.14%
    Market cap $51.64MP/E —
    $3.53$9.12
  • SDEV
    Stablecoin Development Corporation Common Stock
    $0.88
    ▼ 13.73%
    Market cap $52.64MP/E 0.16
    $0.7809$99.75
  • INCR
    Intercure Ltd. Ordinary Shares
    $4.57
    ▼ 1.72%
    Market cap $54.80MP/E —
    $253.3$2,740
  • IMMP
    Immutep Limited American Depositary Shares
    $3.2
    ▼ 0.31%
    Market cap $55.21MP/E —
    $0.022$0.47
  • IBO
    Impact BioMedical Inc. Common Stock
    $2.68
    ▼ 15.14%
    Market cap $48.61MP/E 61.61
    $4.67$10.47

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Institutional Ownership

March 31, 2026

Total shares held
25.8K
Total value held
$15.7K
Institutional holders
6
Top holders this quarter
  • Unknown12.9K
  • Unknown11.4K
  • Unknown996
  • Unknown389
  • Unknown40
  • Unknown1

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.